Answers are grounded in this paper and cite their sources.
No significant EE gap was found for pembrolizumab plus chemotherapy, except in the stratum nonsquamous mNSCLC with <1% PD-L1 tumor expression. In these patients, the survival in real-world was considerably shorter compared to the clinical trial results. Further studies are needed to determine which patient, treatment and or context factors contribute to this disparity.
No takes yet. Share an insight, caveat, or question.
Verschueren et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: